Patrys's PAT-SM6 found safe in myeloma trial
Patrys (ASX:PAB) has revealed that a phase I/IIa trial of its PAT-SM6 drug candidate in multiple myeloma met its primary endpoints of safety and tolerability.
Results from the open-label escalating dose study in 12 patients have been published in the Haematologica journal.
PAT-SM6 was found to be safe and well tolerated at each dose level administered - 0.3, 1, 3 and 6 mg/kg - and the maximum tolerated dose was not reached.
Four of the 12 patients had stable disease after PAT-SM6 treatment across the dose cohorts of over 1 mg/kg, according to the International Myeloma Working Group criteria.
PAT-SM6 targets the GRP78 protein, which plays a role in resistance in many cancers. This could make it an ideal complementary drug in therapeutic strategies for the difficult-to-treat multiple myeloma.
The published study also includes observations on PAT-SM6’s possible role in overcoming tumour resistance.
As well as its clinical program, Patrys has been building up its patent profile for PAT-SM6 in Australia, Europe, North America and Japan.
Patrys (ASX:PAB) shares were trading 5.88% lower at $0.016 as of around 12.30 pm on Wednesday.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
